Clinical-stage Potential PersImmune is a clinical-stage immunotherapy company focused on personalized adoptive cellular therapy for neoantigens (PACTN), presenting a near-term opportunity for partnerships in early-phase trials and potential future commercialization.

Targeted MDS Trial The current Phase 1 trial targets myelodysplastic syndrome, offering a concrete entry point for collaboration with academic centers, biotechs, or bigger pharma seeking to expand immunotherapy capabilities in hematologic malignancies.

Personalized Advantage PACTN uses patient-specific tumor DNA alterations to generate highly specific T-cells with fewer side effects, a compelling value proposition for sponsors aiming to differentiate their immunotherapy portfolios with safer, tolerable treatments.

Funding Readiness With revenue in the sub-one-million range and a lean team, PersImmune may be receptive to co-development, grant, or milestone-based partnerships that minimize upfront risk while enabling technology validation.

Strategic Fit The company’s focus on personalized, non-edited autologous cells complements larger players’ unmet needs in neoantigen targeting, offering potential collaboration avenues in clinical development, manufacturing, or data/biomarker integration to de-risk trial execution.